Download Files:
BEBT-109
SKU
HY-W423595-Get quote
Category Reference compound
Tags Cancer, EGFR, JAK/STAT Signaling, Protein Tyrosine Kinase/RTK
Size – Get quote
Products Details
Product Description
– BEBT-109 is a potent pan-mutant-selective EGFR inhibitor. BEBT-109 has improved pharmacokinetic properties. BEBT-109 can be used for multiple mutant-EGFR-driven non-small cell lung cancer (NSCLC) research[1].
Web ID
– HY-W423595
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C27H32N8O3
References
– [1]Fan F, et al BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer. Transl Oncol. 2021 Feb;14(2):100961.
CAS Number
– 2050906-40-4
Molecular Weight
– 516.59
SMILES
– C=CC(NC1=CC(NC2=NC=CC(N3C=CC4=NC(OC)=CC=C43)=N2)=C(OC)C=C1N(CCN(C)C)C)=O
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– EGFR
Pathway
– JAK/STAT Signaling, Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.